Journal
TRENDS IN PARASITOLOGY
Volume 34, Issue 3, Pages 178-179Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.pt.2017.12.002
Keywords
-
Categories
Funding
- National Institutes of Health [R01AI114685, R01AI124046, R21AI127594]
Ask authors/readers for more resources
Decades after the last new chemical entity was added to the pharmacopeia for human African trypanosomiasis (or sleeping sickness), orally dosed fexinidazole stands poised to replace the current treatment regimen for Trypanosoma brucei gambiense infections, following a positive Phase 2/3 clinical trial.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
